Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Anima Biotech has demonstrated positive preclinical data in idiopathic pulmonary fibrosis using a novel small molecule that modulates mRNA biology. The candidate shows efficacy and safety superior to standard-of-care drugs in animal models and patient-derived tissue explants. The company’s AI-driven platform enables discovery of new druggable targets previously considered “undruggable.” Strategic partnerships with AbbVie, Takeda, and Eli Lilly validate the approach.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Anima Care.